A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome

Area of Science:

• Microbiology
• Pharmacology
• Gastroenterology

Background:

• Broad-spectrum antibiotics can severely disrupt the gut microbiome, leading to adverse health effects.
• Selective antibiotic development aims to mitigate these negative consequences.
• Debio 1452 is an investigational Staphylococcus-selective enoyl-acyl carrier protein reductase (FabI) inhibitor.

Purpose of the Study:

• To evaluate the impact of the pathogen-selective antibiotic Debio 1452 on the mouse gut microbiome.
• To compare Debio 1452's effects with those of commonly used broad-spectrum oral antibiotics.

Main Methods:

• Oral administration of Debio 1452 or broad-spectrum antibiotics to mice for 10 days.
• Analysis of gut bacterial abundance and composition at various time points.
• Assessment of microbiome recovery after antibiotic cessation.

Main Results:

• Debio 1452 treatment resulted in minimal disturbance to gut bacterial abundance and composition.
• Broad-spectrum antibiotics caused significant decreases in bacterial abundance (100- to 4,000-fold) and altered microbial composition.
• Gut microbiome in Debio 1452-treated mice returned to baseline levels within 2 days post-treatment.
• Broad-spectrum antibiotic-treated mice showed delayed recovery (up to 7 days) and persistent compositional changes (up to 20 days).

Conclusions:

• Pathogen-selective antibiotic development, exemplified by Debio 1452, significantly minimizes gut microbiome disturbance compared to broad-spectrum agents.
• This approach preserves gut microbial homeostasis and facilitates rapid recovery.
• Selective antibiotics represent a promising strategy for maintaining gut health during infection treatment.